Literature DB >> 32594123

Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study.

Ryu Watanabe1,2.   

Abstract

Entities:  

Year:  2020        PMID： 32594123     DOI： 10.1093/rheumatology/keaa253

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  2 in total

1.  Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study: reply.

Authors:  Yoshikazu Nakaoka; Katsuhisa Yamashita; Shinji Yamakido
Journal:  Rheumatology (Oxford)       Date:  2020-09-01       Impact factor: 7.580

Review 2.  Cellular Signaling Pathways in Medium and Large Vessel Vasculitis.

Authors:  Ryu Watanabe; Gerald J Berry; David H Liang; Jörg J Goronzy; Cornelia M Weyand
Journal:  Front Immunol       Date:  2020-09-25       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.